Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Mesenchymal stromal cell exosome -treated monocytes and uses thereof

A mononuclear cell and exosome technology, applied in animal cells, vertebrate cells, bone/connective tissue cells, etc., can solve the problems of lack of treatment, fatal IPF, and survival rate less than 10%

Pending Publication Date: 2021-03-09
CHILDRENS MEDICAL CENT CORP
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Lack of complete understanding of the underlying mechanisms of the disease can lead to lack of successful treatment
Despite two newly approved drugs, IPF remains deadly, with less than 10% five-year survival rate

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mesenchymal stromal cell exosome -treated monocytes and uses thereof
  • Mesenchymal stromal cell exosome -treated monocytes and uses thereof
  • Mesenchymal stromal cell exosome -treated monocytes and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0082] Idiopathic pulmonary fibrosis (IPF) is a chronic progressive respiratory disease whose underlying mechanisms are not fully understood and currently lack effective treatments. Although treatment with mesenchymal stromal cells (MSCs) has provided promising results in the prevention of pulmonary fibrosis, limitations of cell therapy continue to make cell-free therapies highly desirable. In preclinical models other than IPF, MSC extracellular vesicles (EVs) or more specifically exosomes (MEx) isolated from the MSC secretome have been shown to serve as therapeutic vehicles. The role of MEx and its mechanism of action (MOA) in IPF are unclear.

[0083] Objective: To study the potency and MOA of MEx in the bleomycin-IPF model.

[0084]METHODS: Exosomes (MEx) isolated from human bone marrow MCS were injected into adult C57BL / 6 mice 0 or 7 days after intratracheal bleomycin instillation. Lung and bone marrow-derived mononuclear cells (BMDMo) were collected on days 7 and 14 for...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Provided herein are methods of modulating monocyte phenotypes using isolated mesenchymal stem cell (MSC) exosomes. Monocytes treated with MSC exosomes can be used to treat fibrotic disease and autoimmune diseases.

Description

[0001] related application [0002] This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Application No. 62 / 669,324, filed May 9, 2018, entitled "MESENCHYMALSTROMAL CELL EXOSOME-TREATED MONOCYTES AND USES THEREOF," the entire contents of which are incorporated by reference Incorporated into this article. Background technique [0003] Idiopathic pulmonary fibrosis (IPF) is a chronic progressive respiratory disease with a prevalence of 0.5 to 27.9 per 100,000 person-years. Lack of a complete understanding of the mechanisms underlying this disease can lead to a lack of successful treatment. Despite two newly approved drugs, IPF remains fatal, with a five-year survival rate of less than 10%. Contents of the invention [0004] Here we show that a single intravenous (IV) dose of mesenchymal stem cell (MSC) exosomes reverses bleomycin-induced lung fibrosis at least in part by modulating the monocyte phenotype and reducing Alveolar epithelial cells (AEC...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K35/15C12N5/0786
CPCA61K35/28A61K35/51C12N5/0645C12N2502/1358A61P11/00A61P29/00A61K31/496A61K31/4418A61K39/4622A61K2239/31A61K39/4614A61K2239/38A61K39/464A61P37/02A61K35/15A61K45/06
Inventor 斯特兰·库雷姆巴纳斯S·亚历山大·米特西利斯
Owner CHILDRENS MEDICAL CENT CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com